Measurement of Fibrinogen in Patients With Systemic Inflammatory Response Syndrome (SIRS), Sepsis or Chronicle Liver Disease on Intensive Care Units (ICU)

NCT ID: NCT01169168

Last Updated: 2010-07-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study patients with

1. chronicle liver diseases

* primary biliary cirrhosis
* primary sclerosing cholangitis
* alcoholic liver cirrhosis
* hepatitis b or C
* Wilson's disease
* cryptogenic cirrhosis
2. Septic Inflammatory Response Syndrome (SIRS)

* sepsis
* septic shock
3. patients after lysis

should be included

Blood samples will be gathered from the patients to measure fibrinogen with 5 different methods.

The methods are:

* Clauss fibrinogen
* PT-Derived fibrinogen
* immunoturbidimetric method
* heat-precipitated fibrinogen
* Schulz fibrinogen

The result of these tests will be correlated with laboratory values which are gathered in routine and the clinical outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SIRS Sepsis Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* SIRS
* sepsis
* septic shock
* chronicle liver disease (MELD-Score \>10)
* patient after lysis
* patient agrees

Exclusion Criteria

* no agreement
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Johann Wolfgang Goethe University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Johann Wolfgang Goethe University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Johann Wolfgang Goethe University Hospital

Frankfurt am Main, Hesse, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Wolfgang Miesbach

Role: primary

+49696301 ext. 7788

Alexander Ferlemann

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FibICU

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.